CClinicalTrials.gg
CompletedNCT05691413Updated Nov 29, 2023

Safety and Efficacy of Facial Cleanser

An interventional study of Other: Product X facial cleanser in Healthy, sponsored by Ungku Shahrin Medical Aesthetic Research & Innovation (USMARI) Centre. Completed at 1 site in Malaysia. Open to participants aged 35 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-11-29.

Sponsored by Ungku Shahrin Medical Aesthetic Research & Innovation (USMARI) Centre · Not applicable, Interventional, and Other

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
35 Years to 55 Years
Sex
All
01

Study summary

This study is conducted to evaluate the safety and effectiveness of facial cleanser X containing combination of olive oil, virgin coconut oil, butylene glycol and hyaluronic acid on skin hydration and skin elasticity. The study duration is 5 weeks and the skin assessment will be carried out at baseline, week 3 and week 5.The main questions this study aims to answer are:

  1. The effect of product on skin hydration.
  2. The effect of product on skin elasticity.
  3. To observe any adverse effect occurrence with the usage of the product.
02

Conditions studied

  • Healthy

Keywords

  • Aesthetic
  • Cosmetic
03

In context

Lead sponsor

Ungku Shahrin Medical Aesthetic Research & Innovation (USMARI) Centre is the lead sponsor of 7 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
35 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Malaysia citizen
  • Male and female (age 35-55 years old)

Exclusion criteria

Exclusion Criteria:

  • Participants who have acne which require medical treatment.
  • Participants taking isotretinoin
  • Participants who had undergo any cosmetic procedures such as laser \& light treatment, botulinum toxin A injections and chemical peeling for the past 3 months
  • Participants who are immunocompromised
  • Participants with history of facial surgery
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    Product X facial cleanser

    Participants will used Product X facial cleanser twice daily for 5 weeks

    Other: Other: Product X facial cleanser

Interventions

  • OtherOther: Product X facial cleanser

    Product X facial cleanser contain olive oil, virgin coconut oil, butylene glycol and hyaluronic acid

06

What researchers measure

Primary outcomes

  1. Change in skin hydration from baseline and at week 3 and 5 after using facial cleanser X

    Skin hydration will be assessed using JANUS III skin analyzer

    Time frame: Baseline, week 3 and week 5

  2. Change in skin elasticity from baseline and at week 3 and 5 after using facial cleanser X

    Skin elasticity will be assessed using JANUS III skin analyzer

    Time frame: Baseline, week 3 and week 5

  3. Adverse effect after using facial cleanser X

    Based on adverse effect occurrence on participants that occur during study period (5 weeks)

    Time frame: Week 5

07

Study locations

1 site
  • Ungku Shahrin Medical Aesthetic Research & Innovation (USMARI) Centre
    Petaling Jaya, Selangor 47810, Malaysia
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 29, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05691413
Lead sponsor
Ungku Shahrin Medical Aesthetic Research & Innovation (USMARI) Centre
Responsible party
Sponsor
First posted
Jan 20, 2023
Start date
Dec 1, 2022
Primary completion
Aug 31, 2023
Completion
Sep 30, 2023
Last update
Nov 29, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion